Glenmark's interim data from PMS Study on Favipiravir released
The study was conducted in patients with mild to moderate COVID-19
The study was conducted in patients with mild to moderate COVID-19
First company in the world to launch Ryaltris-AZ, as a novel fixed dose combination of Mometasone furoate 50 mcg + Azelastine 140 mcg
Subscribe To Our Newsletter & Stay Updated